Evidence map›Paper›PMID 34876113›Full record

ArticleBMC health services research2021

Transparency in public pharmaceutical sector: the key informants' perceptions from a developing country.

Atefeh Esfandiari, Vahid Yazdi-Feyzabadi, Leila Zarei, Arash Rashidian, Hedayat Salari

Abstract read
In one paragraph

Article in BMC health services research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Expectations Shaped Elsewhere: Refugee Experiences of Healthcare in Aotearoa New Zealand.Health expectations : an international journal of public participation in health care and health policy · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Atefeh EsfandiariDepartment of Health Policy & Management, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran.
Vahid Yazdi-FeyzabadiHealth Services Management Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Leila ZareiHealth Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Fars, Iran.
Arash RashidianDepartment of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Hedayat SalariDepartment of Health Policy & Management, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran. Salarihedayat@gmail.com.

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundPolicymaking in the pharmaceutical sector plays a pivotal role in achieving the health systems' goals. Transparency in the pharmaceutical policy could increase confidence in decision-making processes. This study aims to assess transparency in the public pharmaceutical sector of Iran.

methodsThis qualitative study with a content analysis approach was conducted in 2017 using the World Health Organization tool to explore pharmaceutical transparency. The perceptions of the various stakeholders of the health system through semi-structured interviews with a maximum variation of stakeholders were obtained in eight functions, including registration, licensing, inspection, promotion, clinical trials, selection, procurement, and distribution of medicines.

resultsThere are some problems in two main categories: (1) General problems, including lack of transparency, conflict of interest, centralization, and monopoly. (2) Ethical problems include illegal payments, gifts, bribes, conflicts of interest, hidden power, hoarding, relationship-oriented behavior, medicine trafficking, and counterfeit medicine. Suggested solutions include evidence-based decision-making, the use of transparent and accountable processes, standardization, needs assessment, declaring a conflict of interest, skilled human resources, and tracking prescription.

conclusionDespite the development of effective pharmaceutical policy in the health care system and government interventions for the control of the market, in some functions, reviewing the pharmaceutical policy is essential. Additionally, declaring a conflict of interest statement must be at the core of policy development to provide greater transparency.

Indexed as

Developing CountriesPharmaceutical PreparationsDelivery of Health CareHumansPolicy MakingPublic SectorPharmaceutical PreparationsEvidencePharmaceutical sectorPublic sectorStewardshipTransparency

Identifiers

PMID34876113
PMCPMC8653549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.